Bilimsel Makale Arama | NeuralCipher AI

Kaynak kaydı

Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease.

Yu EC, Zhou H, Yan X, Logan KM, Li D, Gulati A, Poremba KE, Ardolino MJ, Su J, Xiao D, Palte RL, McMinn SE, Nogle LM, Adpressa DA, Burgess SA, Xiong T, Otte KM, Chobanian HR, Bass A, Lee S, Pearson K, Messina E, Parisi M, Barnum J, Sobol Z, Ciaccio PJ, DiMauro EF, Fell MJ, Fuller PH.

J Med Chem · 2026-03-29

DOI: 10.1021/acs.jmedchem.6c00238PMID: 41906303

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.

Wan J, Pan H, Chang D, Zhao Y, Xu Q, Yao L, Sun Q, Zhang X, He R, Wang C, Zhang H, Lei L, Wang Y, Li M, Wu H, Ma J, Wu Y, Xu Y, Xiong N, Wang T, Wang X, Chen L, Xu Y, Cao H, Zhang K, Liu W, Zhang Y, Mao C, Wang Q, Xue Z, Zhang Z, Cheng O, Huang W, Zhao G, Cui G, Chen T, Wang P, Di W, Liu H, Zheng H, Chen C, Guo H, Xia K, Zhang Z, Yuan K, Li J, Wang J, Guo J, Shen L, Jiang H, Liu C, Liu J, Chan P, Liu Z, Tang B, Parkinson’s Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD-MDCNC), China Essential Tremor Alliance (CETA).

NPJ Parkinsons Dis · 2026-03-28

DOI: 10.1038/s41531-026-01315-wPMID: 41904258

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Erratum for the Research Article "Parkinson's VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B" by P. Pal <i>et al</i>.

Yazar bilgisi kaynakta kontrol edilmeli

Sci Adv · 2026-03-27

DOI: 10.1126/sciadv.aeg9560PMID: 41894517

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.

Mabrouk OS, Tichler B, Arnold HM, Thoma EC, Alexanian SM, Chen J, Liu TY, Hirschhorn B, Llorens Arenas R, Annand JW, Kapadnis U, Shomo AA, Glajch KE, Ferber K, Moroishi Y, Czerkowicz J, Inra J, Postuma RB, Gurevich T, Mir P, Morris HR, Aldred J, Brodsky MA, Ellenbogen A, Larson D, Tolleson CM, Siderowf A, Tzoulis C, Balaguer E, Marti MJ, Zhao HT, Kordasiewicz HB, Lane R, Hirst WD, Fradette S, Graham DL.

Nat Med · 2026-03-24

DOI: 10.1038/s41591-026-04262-4PMID: 41876647

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Mechanistic of LRRK2-Mediated Pyroptosis Via the NLRP3/Caspase-1/GSDMD Pathway in Parkinson's Disease Progression.

Li J, Zheng Z, Zhang X, Shen L, Xue C, Lu L, Xu X, Li F, Lu G.

Inflammation · 2026-03-14

DOI: 10.1007/s10753-026-02475-wPMID: 41831074

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

LRRK2 kinase mediates increased GCase activity in microglia in response to IFNγ-induced proinflammatory stimulation.

MacDougall EJ, Chen CX, Deneault E, You Z, Kalaydjian D, Abdian N, Durcan TM, Senkevich K, Gan-Or Z, Fon EA.

NPJ Parkinsons Dis · 2026-03-06

DOI: 10.1038/s41531-026-01310-1PMID: 41786767

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

Advancing Development of LRRK2-Targeted Therapeutics for Parkinson's Disease: Conference Proceedings and Roadmap for Research.

Predmore Z, Donofry SD.

Rand Health Q · 2026-03-05

DOI: 10.7249/rhq-13-02-02PMID: 41821671

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

The Age at Onset of LRRK2 p.Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin.

Lüth T, Laabs BH, Sendel S, König IR, Caliebe A, Noyce AJ, Screven LA, Bardien S, Farrer M, Hentati F, Amouri R, Klein C, Sassi SB, Trinh J, Global Parkinson's Genetics Program (GP2).

Ann Neurol · 2026-02-24

DOI: 10.1002/ana.78181PMID: 41735653

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

APOE, Aβ42, and tau differentially impact cognitive decline in Sporadic, GBA1 and LRRK2 Parkinson's disease.

Botta R, Locascio JJ, Ye R, Goodheart AE, Gomperts SN.

NPJ Parkinsons Dis · 2026-02-23

DOI: 10.1038/s41531-026-01290-2PMID: 41730900

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kaynak kaydı

CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.

Chen S, Shen Y, Shao J, Li R, Hao X, Yang H, Ma K, Zhang J.

Auton Neurosci · 2026-02-18

DOI: 10.1016/j.autneu.2026.103399PMID: 41762849

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

Membrane Dysfunction as a Central Mechanism in LRRK2-Associated Parkinson's Disease: Comparative Analysis of G2019S and I1371V Variants.

Singh K, Banerjee R, Potdar C, Shaw A, Rakshith R, Kamble N, Holla V, Yadav R, Pal PK, Datta I.

Cells · 2026-02-13

DOI: 10.3390/cells15040342PMID: 41744785

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Açık erişim

LRRK2<sup>R1627P</sup> mutation amplifies environmental risk factors induced chronic inflammation and α-synuclein aggregation in the gut of rats.

Pang S, Lu J, Wang Y, Ying C, Zhao C, Yue Z, Yang Q, Chan P.

NPJ Parkinsons Dis · 2026-02-07

DOI: 10.1038/s41531-026-01281-3PMID: 41654526

Europe PMC üzerinden doğrulanabilir bibliyografik kayıt.

Makale detayına git Kaynağa git ↗

Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.

785 makale bulundu

Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease.

The genetic spectrum of LRRK2 variants in Parkinson's disease: findings from a large Chinese cohort.

Erratum for the Research Article "Parkinson's VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B" by P. Pal <i>et al</i>.

LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.

Mechanistic of LRRK2-Mediated Pyroptosis Via the NLRP3/Caspase-1/GSDMD Pathway in Parkinson's Disease Progression.

LRRK2 kinase mediates increased GCase activity in microglia in response to IFNγ-induced proinflammatory stimulation.

Advancing Development of LRRK2-Targeted Therapeutics for Parkinson's Disease: Conference Proceedings and Roadmap for Research.

The Age at Onset of LRRK2 p.Gly2019Ser Parkinson's Disease Across Ancestries and Countries of Origin.

APOE, Aβ42, and tau differentially impact cognitive decline in Sporadic, GBA1 and LRRK2 Parkinson's disease.

CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.

Membrane Dysfunction as a Central Mechanism in LRRK2-Associated Parkinson's Disease: Comparative Analysis of G2019S and I1371V Variants.

LRRK2<sup>R1627P</sup> mutation amplifies environmental risk factors induced chronic inflammation and α-synuclein aggregation in the gut of rats.

Filtreler